2 reports of this reaction
1.4% of all LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE reports
#13 most reported adverse reaction
GASTROOESOPHAGEAL REFLUX DISEASE is the #13 most commonly reported adverse reaction for LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE, manufactured by Aurohealth LLC. There are 2 FDA adverse event reports linking LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE to GASTROOESOPHAGEAL REFLUX DISEASE. This represents approximately 1.4% of all 142 adverse event reports for this drug.
Patients taking LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE who experience gastrooesophageal reflux disease should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
GASTROOESOPHAGEAL REFLUX DISEASE is a less commonly reported adverse event for LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE, but still significant enough to appear in the safety profile.
In addition to gastrooesophageal reflux disease, the following adverse reactions have been reported for LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE:
The following drugs have also been linked to gastrooesophageal reflux disease in FDA adverse event reports:
GASTROOESOPHAGEAL REFLUX DISEASE has been reported as an adverse event in 2 FDA reports for LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE. This does not prove causation, but indicates an association observed in post-market surveillance data.
GASTROOESOPHAGEAL REFLUX DISEASE accounts for approximately 1.4% of all adverse event reports for LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE, making it a notable side effect.
If you experience gastrooesophageal reflux disease while taking LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.